Safety and effectiveness have been established in 3 clinical trials in patients 12 years and older Safety and effectiveness in pediatric patients < 12 years have not been established Intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. The growth of pediatric patients receiving intranasal corticosteroids, including Dymista, should be monitored routinely Information on dosing, adverse reactions, and clinical trials New drug
|